13F Holdings
中文EN

BCDA BioCardia, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 925741 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-3.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-950.1%
ROA-230.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets73.8%
Debt / equity0.00x
Current ratio1.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-22.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$58,000$477,000$1.35M$1.01M
Cost of revenue————$0
Gross profit————$1.01M
R&D expense$4.96M$4.39M$7.73M$8.83M$8.56M
SG&A expense$3.32M$3.67M$4.39M$4.42M$5.09M
Operating income-$8.28M-$8.00M-$11.64M-$11.90M-$12.63M
Interest expense————$0
Income tax$0$0$0$0$0
Net income-$8.23M-$7.95M-$11.57M-$11.91M-$12.62M
EBITDA-$8.25M-$7.93M-$11.56M-$11.82M-$12.57M
EPS (basic)-1.23-2.90-8.19-0.67-0.75
EPS (diluted)————-0.75
Weighted avg. shares (diluted)————16.92M
Balance sheet
Cash & equivalents$2.50M$2.37M$1.10M$7.36M$12.87M
Receivables$20,000$0$63,000$201,000$147,000
Current assets$2.73M$2.62M$1.46M$7.86M$13.48M
PP&E, net$16,000$33,000$94,000$170,000$182,000
Total assets$3.41M$3.72M$2.99M$9.79M$15.72M
Current liabilities$2.43M$2.32M$3.61M$3.58M$3.71M
Total liabilities$2.52M$2.89M$4.59M$4.90M$5.34M
Shareholders' equity$895,000$837,000-$1.60M$4.89M$10.38M
Shares outstanding10.76M4.60M1.58M20.08M16.87M
Cash flow statement
Operating cash flow-$7.44M-$7.89M-$9.97M-$10.56M-$10.37M
Capital expenditure$7,000$6,000$12,000$70,000$116,000
Free cash flow-$7.44M-$7.89M-$9.99M-$10.63M-$10.48M
Investing cash flow-$7,000-$6,000-$12,000-$70,000-$116,000
Financing cash flow$7.57M$9.16M$3.73M$5.12M$1.95M
Depreciation & amortization$24,000$67,000$84,000$82,000$60,000
Stock-based compensation$430,000$741,000$1.03M$1.18M$1.66M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.